BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina S. Pedersen, Joon Oh Park, Robert A. Ramirez, David G. Abad, Jaime Feliu, Andres Muñoz, Mariano Ponz-Sarvise, Amnon Peled, Tzipora M. Lustig, Osnat Bohana-Kashtan, Stephen M. ShawElla Sorani, Marya Chaney, Shaul Kadosh, Abi Vainstein Haras, Daniel D. Von Hoff, Manuel Hidalgo

Research output: Contribution to journalArticlepeer-review

175 Scopus citations

Fingerprint

Dive into the research topics of 'BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds